Skip to content

Comparison of the prognosis of patients undergoing simultaneous versus non-simultaneous combined laryngeal-tracheal-oesophageal-thyroid multi-organ cluster transplantation after total laryngectomy: a prospective, single-centre, open-label, non-randomised controlled clinical study

Comparison of the prognosis of patients undergoing simultaneous versus non-simultaneous combined laryngeal-tracheal-oesophageal-thyroid multi-organ cluster transplantation after total laryngectomy: a prospective, single-centre, open-label, non-randomised controlled clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084140
Enrollment
Unknown
Registered
2024-05-11
Start date
2024-05-13
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal transplantation

Interventions

Test Group:Simultaneous laryngal-tracheal transplantation after total laryngectomy
Control Group:non-simultaneous laryngal-tracheal transplantation after total laryngectomy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients enrolled in the experimental group must satisfy both (1), (2), (5), (6), (7) and (8) of the following criteria; patients enrolled in the control group must satisfy both (3), (4), (5), (6), (7) and (8) of the following criteria: (1) Patients who need total laryngectomy due to various causes (including but not limited to advanced laryngeal cancer, laryngeal cancer recurrence, hypopharyngeal and cervical esophageal cancer, tongue cancer, trauma, postoperative recurrence of advanced thyroid cancer, etc.); (2) patients under 75 years old (including 75 years old) with urgent needs for voice function; (3) patients who underwent total laryngectomy due to various causes (including but not limited to advanced laryngeal cancer, laryngeal cancer recurrence, hypopharyngeal and cervical esophageal cancer, tongue cancer, trauma, recurrence of advanced thyroid cancer, etc.); (4) those who are under 75 years old (including 75 years old), have lived "laryngfree" for more than one year, and have an urgent need for voice function or are related practitioners who need to use voice frequently; (5) patients with good general condition or combined with hypertension, diabetes, coronary heart disease, thyroid dysfunction, liver and kidney dysfunction and other basic diseases could be treated by surgery after multi-disciplinary consultation; (6) patients who are willing to take immunosuppressive drugs for life, or who have been required to take immunosuppressive drugs for life due to other causes (such as other organ transplantation, some rheumatic diseases, etc.); (7) Patients and their family members (main accompany) have certain language, reading, writing and communication skills to facilitate the filling of the questionnaire; (8) Voluntarily participate in the study after informed consent and can return to the hospital on time for follow-up.

Exclusion criteria

Exclusion criteria: Patients were not enrolled if they met any of the following criteria: (1) Patients older than 75 years with no urgent need for laryngeal function such as voice function; (2) Patients with poor general condition who could not tolerate laryngotracheal transplantation and lifelong immunosuppressive therapy; (3) The patients were living with tumor after total laryngectomy (including but not limited to local recurrence, distant metastasis, and new tumors in other sites); (4) patients who suffered from mental or psychological disorders before total laryngectomy.

Design outcomes

Primary

MeasureTime frame
Postoperative adverse event incidence rate;

Secondary

MeasureTime frame
Overall Survival;Disease Free Survival;Graft Survival;Rrecovery time of Voice function;

Countries

China

Contacts

Public ContactChen Fei

West China Hospital, Sichuan University

hxchenfei@163.com+86 189 8060 2124

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026